Bruno Allolio

Bruno Allolio

Auto-generated profile, based on publicly available information

Bruno Allolio

Department of Internal Medicine I (B.A.), University Hospital, University of Würzburg, 97070 Würzburg, Germany

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2002 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
BABruno Allolio
Bruno Allolio
WAWiebke Arlt
Wiebke Arlt

1 December 2013 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
TKT. M. Kerkhofs
T. M. Kerkhofs
EBE. Baudin
E. Baudin
Massimo TerzoloMassimo Terzolo
Massimo Terzolo
BAB. Allolio
B. Allolio
RCR. Chadarevian
R. Chadarevian
MFM. Fassnacht
M. Fassnacht
Context: Mitotane is the only approved drug for treatment of adrenocortical carcinoma. Its pharmacokinetic properties are not fully elucidated and different dosing regimens have never been compared head to head. Objective: The objective of the study was to investigate the relationship between mitotane dose and plasma concentration comparing two dosing regimens. Design/Setting: This was a prospective, open-label, multicenter trial of a predefined duration of 12 weeks. Patients/Interventions: Forty mitotane-naïve patients with metastatic adrenocortical carcinoma were assigned to a predefined low- or high-dose regimen by the local investigator. Thirty-two patients could be evaluated in detail. Main Outcome Measure: The difference in median mitotane plasma levels between both treatment groups was measured. Results: Despite a difference in mean cumulative dose (440 ± 142 g vs 272 ± 121 g), median maximum plasma levels were not significantly different between the two groups [high dose 14.3 mg/L (range 6.3–29.7, n = 20) vs 11.3 mg/L (range 5.5–20.0, n = 12), P = .235]. Ten of 20 patients on the high-dose regimen reached plasma concentrations of 14 mg/L or greater after 46 days (range 18–81 d) compared with 4 of 12 patients on the low-dose regimen after 55 days (range 46–74 d, P = .286). All patients who reached 14 mg/L at 12 weeks displayed a level of 4.1 mg/L or greater on day 33 (100% sensitivity). There were no significant differences in frequency and severity of adverse events. Among patients not receiving concomitant chemotherapy mitotane exposure was higher in the high-dose group: 1013 ± 494 mg/L · d vs 555 ± 168 mg/L · d (P = .080). Conclusions: The high-dose starting regimen resulted in neither significantly different mitotane levels nor a different rate of adverse events, but concomitant chemotherapy influenced these results. Thus, for mitotane monotherapy the high-dose approach is favorable, whereas for combination therapy a lower dose seems reasonable.

9 November 2012 in Hormone and Metabolic Research
Verified
Journal Article
Closed access
PDF file
SSSilviu Sbiera
Silviu Sbiera
MKMatthias Kroiss
Matthias Kroiss
TTT. Thamm
T. Thamm
MBM. Beyer
M. Beyer
FMF. Majidi
F. Majidi
MFM. Fassnacht
M. Fassnacht
Treatment options for adrenocortical carcinoma (ACC) are very limited. In other solid tumors, small vaccination trials targeting the anti-apoptotic molecule survivin suggested immunological and clinical benefit in selected patients. Therefore, we investigated whether survivin might be a suitable target for immunotherapy in ACC. Survivin mRNA and protein expression was assessed in adrenal tissue specimens [by real-time-PCR in 29 ACC, 24 adrenocortical adenomas (ACA) and 12 normal adrenal glands; by immunohistochemistry in 167 ACCs, 15 ACA, and 5 normal adrenal glands]. Expression was correlated with clinical outcome using Kaplan–Meier and Cox regression analyses. The anti-apoptotic role of survivin was investigated in the SW13 ACC cell line using survivin siRNA. The presence of spontaneous survivin specific T-cells in peripheral blood was assessed by FACS dextramere staining in 29 ACC patients in comparison to healthy controls. Survivin mRNA in ACC was significantly overexpressed when compared with ACA or normal adrenal glands. Immunohistochemistry confirmed survivin protein expression in 97% of the ACCs. In 83% of samples, staining was moderate or high and clinical outcome in this subgroup showed a trend towards poorer prognosis [hazard ratio for death 2.28 (95% CI 0.99–5.28); p=0.053]. Survivin knockdown in SW-13 cell significantly increased the rate of apoptosis. Finally, spontaneous survivin-reactive T cells were detectable in 3 of 29 ACC patients. In conclusion, our data suggest that survivin could play an important role in the anti-apoptotic mechanisms in ACC and provide first hints that targeting survivin might be an interesting new therapeutic approach in this rare disease.

1 December 2007
Verified
Journal Article
Closed access
SFS Frantz
S Frantz
KHK Hu
K Hu
JWJ Widder
J Widder
BWB Weckler
B Weckler
HSH Scheuermann
H Scheuermann
BAB Allolio
B Allolio

7 March 2013 in Experimental and Clinical Endocrinology & Diabetes
Verified
Journal Article
Closed access
FBF Beuschlein
F Beuschlein
JOJ Obracay
J Obracay
WSW Saeger
W Saeger
MPMartin Reincke Prof
Martin Reincke Prof
RLR Libe
R Libe
MFM Fassnacht
M Fassnacht
Purpose: Recurrence of adrenocortical cancer (ACC) even after complete resection is a common clinical problem. The aim of this study was the identification of histological parameters with potential prognostic value. Patients and methods: From the German ACC registry 318 patients with ENSAT stage I-III were identified with R0 resection for whom histological analysis was available. Histological markers were correlated with recurrence free and overall survival. As an independent validation cohort 250 patients from six European centers were utilized. Results: Within the German cohort, univariate analysis identified age at diagnosis, tumor size and lymph node positivity as markers with predictive value for recurrence free survival (RFS). Accordingly, ENSAT staging was also of significance (p = 0.02). Ki67 index provided the single best prognostic value for recurrence free survival (HR 1.042 per % increase for the German cohort and HR 1.024 for the validation cohort; p < 0.001) which was superior to markers evaluated for calculation of the Weiss score. Following multivariate analysis including age, tumor size and adjuvant mitotane treatment Ki67 index remained informative. Similar results were obtainable for overall survival (HR 1.051 per % increase for the German cohort and HR 1.023 for the validation cohort; p < 0.001). Conclusion: In conclusion, Ki67 was identified as the single most important prognostic marker for disease recurrence in ACC patients following R0 resection. Our findings will help to guide decisions on adjuvant therapy for this rare disease.

1 August 2010 in Experimental and Clinical Endocrinology & Diabetes
Verified
Journal Article
Closed access
WFW Fenske
W Fenske
DLD Lorenz
D Lorenz
UHU Haagen
U Haagen
JPJ Papassotiriou
J Papassotiriou
MFM Fassnacht
M Fassnacht
BAB Allolio
B Allolio
Background: The water deprivation test with direct or indirect measurement of plasma vasopressin (AVP) is currently the method of choice for the differential diagnosis of the polydipsia-polyuria syndrome. Its diagnostic reliability, however, has never been evaluated in a larger series of patients, and measurement of AVP is known to be hampered by its high preanalytical instability. This study seeks to evaluate the diagnostic potential of copeptin, a highly stable and easy to measure surrogate of AVP secretion, in a large sample of patients with polyuria-polydipsia syndrome, and to compare its performance with the current diagnostic standard. Methods: Thirty healthy subjects and 50 consecutive patients with polydipsia-polyuria syndrome underwent the standard water deprivation test with additional, iterative measurements of plasma AVP and copeptin levels. A clinical reference standard and patients' response to therapeutic trials adjudicated on the final diagnosis, provided that any diagnostic discrepancies occurred between the water deprivation test and direct AVP measurement. Results: Twenty two patients (44%) were diagnosed with primary polydipsia, 17 patients (34%) with partial central diabetes insipidus (DI), 9 patients (18%) with complete central DI, and 2 patients (4%) with nephrogenic DI. The water deprivation test led to a correct diagnosis in 35/50 patients (70%), additional AVP measurement correctly diagnosed in 23 patients (46%), and additional copeptin measurement correctly identified 36 patients (72%). The ratio between delta copeptin [8h to 16h] and the serum sodium concentration at 16h yielded the best diagnostic accuracy, allowing even to discern mild forms of central DI from primary polydipsia (sensitivity and specificity of 87 and 100%, respectively). Conclusion: Baseline copeptin reliably identified patients with nephrogenic and complete central DI. The ratio of delta copeptin [8h-16h] to plasma osmolality [16h] during an osmotic stimulation holds great potential to considerably improve the differential diagnosis in this diagnostically demanding syndrome.